Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Correction: Focal Adhesion Kinase Targeting Using In vivo Short Interfering RNA Delivery in Neutral Liposomes for Ovarian Carcinoma Therapy.

Halder J, Kamat AA, Landen CN Jr, Han LY, Lutgendorf SK, Lin YG, Merritt WM, Jennings NB, Chavez-Reyes A, Coleman RL, Gershenson DM, Schmandt R, Cole SW, Lopez-Berestein G, Sood AK.

Clin Cancer Res. 2019 May 15;25(10):3194. doi: 10.1158/1078-0432.CCR-19-1132. No abstract available.

PMID:
31092618
2.

Exposure to cuticular bacteria can alter host behavior in a funnel-weaving spider.

Parks OB, Kothamasu KS, Ziemba MJ, Benner M, Cristinziano M, Kantz S, Leger D, Li J, Patel D, Rabuse W, Sutton S, Wilson A, Baireddy P, Kamat AA, Callas MJ, Borges MJ, Scalia MN, Klenk E, Scherer G, Martinez MM, Grubb SR, Kaufmann N, Pruitt JN, Keiser CN.

Curr Zool. 2018 Dec;64(6):721-726. doi: 10.1093/cz/zox064. Epub 2017 Nov 16. Erratum in: Curr Zool. 2018 Jun;64(3):405.

3.

Erratum: Exposure to cuticular bacteria can alter host behavior in a funnel-weaving spider.

Parks OB, Kothamasu KS, Ziemba MJ, Benner M, Cristinziano M, Kantz S, Leger D, Li J, Patel D, Rabuse W, Sutton S, Wilson A, Baireddy P, Kamat AA, Callas MJ, Borges MJ, Scalia MN, Klenk E, Scherer G, Martinez MM, Grubb SR, Kaufmann N, Pruitt JN, Keiser CN.

Curr Zool. 2018 Jun;64(3):405. doi: 10.1093/cz/zoy013. Epub 2018 Feb 6.

4.

Non-16/18 high-risk HPV infection predicts disease persistence and progression in women with an initial interpretation of LSIL.

Lyons YA, Kamat AA, Zhou H, Mody DR, Schwartz MR, Hobday C, Ge Y.

Cancer Cytopathol. 2015 Jul;123(7):435-42. doi: 10.1002/cncy.21549. Epub 2015 Apr 22.

5.

Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma.

Gillet JP, Calcagno AM, Varma S, Davidson B, Bunkholt Elstrand M, Ganapathi R, Kamat AA, Sood AK, Ambudkar SV, Seiden MV, Rueda BR, Gottesman MM.

Clin Cancer Res. 2012 Jun 1;18(11):3197-206. doi: 10.1158/1078-0432.CCR-12-0056. Epub 2012 Apr 5.

6.

Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer.

Coleman RL, Duska LR, Ramirez PT, Heymach JV, Kamat AA, Modesitt SC, Schmeler KM, Iyer RB, Garcia ME, Miller DL, Jackson EF, Ng CS, Kundra V, Jaffe R, Sood AK.

Lancet Oncol. 2011 Nov;12(12):1109-17. doi: 10.1016/S1470-2045(11)70244-3. Epub 2011 Oct 10.

7.

Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer.

Merritt WM, Kamat AA, Hwang JY, Bottsford-Miller J, Lu C, Lin YG, Coffey D, Spannuth WA, Nugent E, Han LY, Landen CN, Nick AM, Stone RL, Coffman K, Bruckheimer E, Broaddus RR, Gershenson DM, Coleman RL, Sood AK.

Cancer Biol Ther. 2010 Dec 15;10(12):1306-14. Epub 2010 Dec 15.

8.

La maladie de Grisel treated by combined C1-2 transarticular and C1 lateral mass screw fixation.

Pereira EA, Hempenstall J, Pretorius PM, Kamat AA, Cadoux-Hudson TA.

Br J Neurosurg. 2010 Aug;24(4):499-501. doi: 10.3109/02688691003710528.

PMID:
20726762
9.

Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis.

Sood AK, Armaiz-Pena GN, Halder J, Nick AM, Stone RL, Hu W, Carroll AR, Spannuth WA, Deavers MT, Allen JK, Han LY, Kamat AA, Shahzad MM, McIntyre BW, Diaz-Montero CM, Jennings NB, Lin YG, Merritt WM, DeGeest K, Vivas-Mejia PE, Lopez-Berestein G, Schaller MD, Cole SW, Lutgendorf SK.

J Clin Invest. 2010 May;120(5):1515-23. doi: 10.1172/JCI40802. Epub 2010 Apr 12.

10.

Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer.

Merritt WM, Nick AM, Carroll AR, Lu C, Matsuo K, Dumble M, Jennings N, Zhang S, Lin YG, Spannuth WA, Kamat AA, Stone RL, Shahzad MM, Coleman RL, Kumar R, Sood AK.

Mol Cancer Ther. 2010 Apr;9(4):985-95. doi: 10.1158/1535-7163.MCT-09-0967. Epub 2010 Apr 6.

11.

Plasma cell-free DNA in ovarian cancer: an independent prognostic biomarker.

Kamat AA, Baldwin M, Urbauer D, Dang D, Han LY, Godwin A, Karlan BY, Simpson JL, Gershenson DM, Coleman RL, Bischoff FZ, Sood AK.

Cancer. 2010 Apr 15;116(8):1918-25. doi: 10.1002/cncr.24997.

12.

Frequent downregulation of miR-34 family in human ovarian cancers.

Corney DC, Hwang CI, Matoso A, Vogt M, Flesken-Nikitin A, Godwin AK, Kamat AA, Sood AK, Ellenson LH, Hermeking H, Nikitin AY.

Clin Cancer Res. 2010 Feb 15;16(4):1119-28. doi: 10.1158/1078-0432.CCR-09-2642. Epub 2010 Feb 9.

13.

Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma.

Merritt WM, Danes CG, Shahzad MM, Lin YG, Kamat AA, Han LY, Spannuth WA, Nick AM, Mangala LS, Stone RL, Kim HS, Gershenson DM, Jaffe RB, Coleman RL, Chandra J, Sood AK.

Cancer Biol Ther. 2009 Aug;8(16):1596-603. Epub 2009 Aug 13.

14.

EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer.

Kamat AA, Coffey D, Merritt WM, Nugent E, Urbauer D, Lin YG, Edwards C, Broaddus R, Coleman RL, Sood AK.

Cancer. 2009 Jun 15;115(12):2684-92. doi: 10.1002/cncr.24335.

15.

Erythropoeisis-stimulating agents (ESAs) in cervix cancer: The "black box" paradox.

Kamat AA, Coleman RL.

Cancer Biol Ther. 2009 Jan;8(1):18-20. Epub 2009 Jan 29. No abstract available.

PMID:
19127119
16.

Dicer, Drosha, and outcomes in patients with ovarian cancer.

Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R, Urbauer D, Pennacchio LA, Cheng JF, Nick AM, Deavers MT, Mourad-Zeidan A, Wang H, Mueller P, Lenburg ME, Gray JW, Mok S, Birrer MJ, Lopez-Berestein G, Coleman RL, Bar-Eli M, Sood AK.

N Engl J Med. 2008 Dec 18;359(25):2641-50. doi: 10.1056/NEJMoa0803785. Erratum in: N Engl J Med. 2010 Nov 4;363(19):1877.

17.

Functional significance of VEGFR-2 on ovarian cancer cells.

Spannuth WA, Nick AM, Jennings NB, Armaiz-Pena GN, Mangala LS, Danes CG, Lin YG, Merritt WM, Thaker PH, Kamat AA, Han LY, Tonra JR, Coleman RL, Ellis LM, Sood AK.

Int J Cancer. 2009 Mar 1;124(5):1045-53. doi: 10.1002/ijc.24028.

18.

Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer.

Landen CN, Kim TJ, Lin YG, Merritt WM, Kamat AA, Han LY, Spannuth WA, Nick AM, Jennnings NB, Kinch MS, Tice D, Sood AK.

Neoplasia. 2008 Nov;10(11):1259-67.

19.

Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth.

Lin YG, Immaneni A, Merritt WM, Mangala LS, Kim SW, Shahzad MM, Tsang YT, Armaiz-Pena GN, Lu C, Kamat AA, Han LY, Spannuth WA, Nick AM, Landen CN Jr, Wong KK, Gray MJ, Coleman RL, Bodurka DC, Brinkley WR, Sood AK.

Clin Cancer Res. 2008 Sep 1;14(17):5437-46. doi: 10.1158/1078-0432.CCR-07-4922.

20.

HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma.

Han LY, Fletcher MS, Urbauer DL, Mueller P, Landen CN, Kamat AA, Lin YG, Merritt WM, Spannuth WA, Deavers MT, De Geest K, Gershenson DM, Lutgendorf SK, Ferrone S, Sood AK.

Clin Cancer Res. 2008 Jun 1;14(11):3372-9. doi: 10.1158/1078-0432.CCR-07-4433.

21.

Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth.

Merritt WM, Lin YG, Spannuth WA, Fletcher MS, Kamat AA, Han LY, Landen CN, Jennings N, De Geest K, Langley RR, Villares G, Sanguino A, Lutgendorf SK, Lopez-Berestein G, Bar-Eli MM, Sood AK.

J Natl Cancer Inst. 2008 Mar 5;100(5):359-72. doi: 10.1093/jnci/djn024. Epub 2008 Feb 26.

22.

Clinical and biological significance of vascular endothelial growth factor in endometrial cancer.

Kamat AA, Merritt WM, Coffey D, Lin YG, Patel PR, Broaddus R, Nugent E, Han LY, Landen CN Jr, Spannuth WA, Lu C, Coleman RL, Gershenson DM, Sood AK.

Clin Cancer Res. 2007 Dec 15;13(24):7487-95.

23.

Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma.

Halder J, Lin YG, Merritt WM, Spannuth WA, Nick AM, Honda T, Kamat AA, Han LY, Kim TJ, Lu C, Tari AM, Bornmann W, Fernandez A, Lopez-Berestein G, Sood AK.

Cancer Res. 2007 Nov 15;67(22):10976-83. Erratum in: Cancer Res. 2018 Jul 15;78(14):4100.

24.

Neuroendocrine modulation of signal transducer and activator of transcription-3 in ovarian cancer.

Landen CN Jr, Lin YG, Armaiz Pena GN, Das PD, Arevalo JM, Kamat AA, Han LY, Jennings NB, Spannuth WA, Thaker PH, Lutgendorf SK, Savary CA, Sanguino AM, Lopez-Berestein G, Cole SW, Sood AK.

Cancer Res. 2007 Nov 1;67(21):10389-96.

25.

Antitumor and antivascular effects of AVE8062 in ovarian carcinoma.

Kim TJ, Ravoori M, Landen CN, Kamat AA, Han LY, Lu C, Lin YG, Merritt WM, Jennings N, Spannuth WA, Langley R, Gershenson DM, Coleman RL, Kundra V, Sood AK.

Cancer Res. 2007 Oct 1;67(19):9337-45.

26.

Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma.

Lu C, Kamat AA, Lin YG, Merritt WM, Landen CN, Kim TJ, Spannuth W, Arumugam T, Han LY, Jennings NB, Logsdon C, Jaffe RB, Coleman RL, Sood AK.

Clin Cancer Res. 2007 Jul 15;13(14):4209-17.

28.

Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway.

Lin YG, Kunnumakkara AB, Nair A, Merritt WM, Han LY, Armaiz-Pena GN, Kamat AA, Spannuth WA, Gershenson DM, Lutgendorf SK, Aggarwal BB, Sood AK.

Clin Cancer Res. 2007 Jun 1;13(11):3423-30.

29.

Relaxin promotes prostate cancer progression.

Feng S, Agoulnik IU, Bogatcheva NV, Kamat AA, Kwabi-Addo B, Li R, Ayala G, Ittmann MM, Agoulnik AI.

Clin Cancer Res. 2007 Mar 15;13(6):1695-702.

30.

Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma.

Lu C, Bonome T, Li Y, Kamat AA, Han LY, Schmandt R, Coleman RL, Gershenson DM, Jaffe RB, Birrer MJ, Sood AK.

Cancer Res. 2007 Feb 15;67(4):1757-68.

31.

Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer.

Kamat AA, Kim TJ, Landen CN Jr, Lu C, Han LY, Lin YG, Merritt WM, Thaker PH, Gershenson DM, Bischoff FZ, Heymach JV, Jaffe RB, Coleman RL, Sood AK.

Cancer Res. 2007 Jan 1;67(1):281-8. Erratum in: Cancer Res. 2018 Jul 15;78(14):4099.

32.

EphA2 overexpression is associated with angiogenesis in ovarian cancer.

Lin YG, Han LY, Kamat AA, Merritt WM, Landen CN, Deavers MT, Fletcher MS, Urbauer DL, Kinch MS, Sood AK.

Cancer. 2007 Jan 15;109(2):332-40.

33.

Quantification of total plasma cell-free DNA in ovarian cancer using real-time PCR.

Kamat AA, Sood AK, Dang D, Gershenson DM, Simpson JL, Bischoff FZ.

Ann N Y Acad Sci. 2006 Sep;1075:230-4.

PMID:
17108216
34.

Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer.

Landen CN, Merritt WM, Mangala LS, Sanguino AM, Bucana C, Lu C, Lin YG, Han LY, Kamat AA, Schmandt R, Coleman RL, Gershenson DM, Lopez-Berestein G, Sood AK.

Cancer Biol Ther. 2006 Dec;5(12):1708-13. Epub 2006 Dec 30.

PMID:
17106249
35.

Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.

Landen CN Jr, Lu C, Han LY, Coffman KT, Bruckheimer E, Halder J, Mangala LS, Merritt WM, Lin YG, Gao C, Schmandt R, Kamat AA, Li Y, Thaker P, Gershenson DM, Parikh NU, Gallick GE, Kinch MS, Sood AK.

J Natl Cancer Inst. 2006 Nov 1;98(21):1558-70.

PMID:
17077358
36.

Analysis of EphA2 expression and mutant p53 in ovarian carcinoma.

Merritt WM, Thaker PH, Landen CN Jr, Deavers MT, Fletcher MS, Lin YG, Han LY, Kamat AA, Schmandt R, Gershenson DM, Kinch MS, Sood AK.

Cancer Biol Ther. 2006 Oct;5(10):1357-60. Epub 2006 Oct 31.

PMID:
16969087
37.

Circulating cell-free DNA: a novel biomarker for response to therapy in ovarian carcinoma.

Kamat AA, Bischoff FZ, Dang D, Baldwin MF, Han LY, Lin YG, Merritt WM, Landen CN Jr, Lu C, Gershenson DM, Simpson JL, Sood AK.

Cancer Biol Ther. 2006 Oct;5(10):1369-74. Epub 2006 Oct 26.

PMID:
16969071
38.

Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma.

Han LY, Landen CN, Trevino JG, Halder J, Lin YG, Kamat AA, Kim TJ, Merritt WM, Coleman RL, Gershenson DM, Shakespeare WC, Wang Y, Sundaramoorth R, Metcalf CA 3rd, Dalgarno DC, Sawyer TK, Gallick GE, Sood AK.

Cancer Res. 2006 Sep 1;66(17):8633-9.

39.

Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy.

Halder J, Kamat AA, Landen CN Jr, Han LY, Lutgendorf SK, Lin YG, Merritt WM, Jennings NB, Chavez-Reyes A, Coleman RL, Gershenson DM, Schmandt R, Cole SW, Lopez-Berestein G, Sood AK.

Clin Cancer Res. 2006 Aug 15;12(16):4916-24. Erratum in: Clin Cancer Res. 2019 May 15;25(10):3194.

40.

Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma.

Thaker PH, Han LY, Kamat AA, Arevalo JM, Takahashi R, Lu C, Jennings NB, Armaiz-Pena G, Bankson JA, Ravoori M, Merritt WM, Lin YG, Mangala LS, Kim TJ, Coleman RL, Landen CN, Li Y, Felix E, Sanguino AM, Newman RA, Lloyd M, Gershenson DM, Kundra V, Lopez-Berestein G, Lutgendorf SK, Cole SW, Sood AK.

Nat Med. 2006 Aug;12(8):939-44. Epub 2006 Jul 23.

PMID:
16862152
41.

The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer.

Kamat AA, Fletcher M, Gruman LM, Mueller P, Lopez A, Landen CN Jr, Han L, Gershenson DM, Sood AK.

Clin Cancer Res. 2006 Mar 15;12(6):1707-14.

42.

Painful third nerve palsy in a patient with perimesencephalic subarachnoid haemorrhage.

Kamat AA, Tizzard S, Mathew B.

Br J Neurosurg. 2005 Jun;19(3):247-50.

PMID:
16455527
43.

Stress hormone-mediated invasion of ovarian cancer cells.

Sood AK, Bhatty R, Kamat AA, Landen CN, Han L, Thaker PH, Li Y, Gershenson DM, Lutgendorf S, Cole SW.

Clin Cancer Res. 2006 Jan 15;12(2):369-75.

44.

Preoperative serum tissue factor levels are an independent prognostic factor in patients with ovarian carcinoma.

Han LY, Landen CN Jr, Kamat AA, Lopez A, Bender DP, Mueller P, Schmandt R, Gershenson DM, Sood AK.

J Clin Oncol. 2006 Feb 10;24(5):755-61. Epub 2005 Dec 27.

PMID:
16380413
45.

The role of relaxin in endometrial cancer.

Kamat AA, Feng S, Agoulnik IU, Kheradmand F, Bogatcheva NV, Coffey D, Sood AK, Agoulnik AI.

Cancer Biol Ther. 2006 Jan;5(1):71-7. Epub 2006 Jan 31.

PMID:
16322684
46.

Endocrine effects of relaxin overexpression in mice.

Feng S, Bogatcheva NV, Kamat AA, Truong A, Agoulnik AI.

Endocrinology. 2006 Jan;147(1):407-14. Epub 2005 Oct 13.

PMID:
16223865
47.

The merits of vascular targeting for gynecologic malignancies.

Kamat AA, Sood AK.

Curr Oncol Rep. 2005 Nov;7(6):444-50. Review.

48.

Genetic targeting of relaxin and insl3 signaling in mice.

Feng S, Bogatcheva NV, Kamat AA, Agoulnik AI.

Ann N Y Acad Sci. 2005 May;1041:82-90.

PMID:
15956690
49.

Protein expression profiling of endometriosis: validation of 2-mm tissue microarrays.

Kamat AA, Younes PS, Sayeeduddin M, Wheeler TM, Simpson JL, Agoulnik AI.

Fertil Steril. 2004 Dec;82(6):1681-3.

PMID:
15589880
50.

Genetic targeting of relaxin and insulin-like factor 3 receptors in mice.

Kamat AA, Feng S, Bogatcheva NV, Truong A, Bishop CE, Agoulnik AI.

Endocrinology. 2004 Oct;145(10):4712-20. Epub 2004 Jul 15.

PMID:
15256493

Supplemental Content

Loading ...
Support Center